no doc loans april 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/4e90d7/vytorin_wave_two) has announced the addition of the "Vytorin: Wave Two - Impact of ENHANCE Trial" report to their offering. A Survey of One-Hundred Three US-based PCP's and Cardiologists Deliverable: Survey with key findings. Study Description: Topic: Vytorin: Wave Two -- Impact of ENHANCE Trial Respondent Type: Physicians Specialties Covered: Primary Care and Cardiology Region: United States Only Methodology - Online survey, self-administered via a Panel Intelligence website - Duration: 10 minutes - Size: 72 PCP's and 31 Cardiologists for 103 respondents - Fielding Dates: April 1st to April 4th, 2008 Inclusion Criteria and Respondent Demographics: - US-based - 2 to 30 years of experience post-training - Minimum of 75% professional time spent in clinical practice - Writes at least 20 prescriptions for Zetia and Vytorin (combined) in an average month Companies Mentioned: - AstraZeneca - Pfizer - Merck/Schering-Plough Pharmaceuticals - Merck & Co For more information visit http://www.researchandmarkets.com/research/4e90d7/vytorin_wave_two COPYRIGHT 2008 Business Wire COPYRIGHT 2008 Gale, Cengage Learning. title 1 loan forgiveness program georgia unsecured loans bad credit apply for personal unsecure loan u s cmbs loan delinquency index auto car loan used